肌阵挛-失张力性癫痫:遗传病因、分类界限与治疗策略更新
该综述更新了肌阵挛-失张力性癫痫的遗传病因、分类界限和治疗策略。该综合征为儿童期起病,传统抗癫痫药物和生酮饮食仍是主要治疗选择,约三分之二患儿可获无认知行为后遗症的缓解,部分仍耐药并伴智力障碍和行为问题。识别单基因病因对个性化治疗有重要意义,但诊断复杂性阻碍了新疗法试验的开展。
要点
- 肌阵挛-失张力性癫痫为儿童期起病,包含肌阵挛-失张力、失张力、肌阵挛、失神及全面强直-阵挛等多种发作类型。
- 传统抗癫痫药物和生酮饮食仍是主要治疗选择;约三分之二患儿可达无认知或行为后遗症的癫痫缓解。
- 部分患儿持续存在耐药性癫痫、智力障碍和行为问题;相当一部分患者可发现单基因病因,提示基因检测对个性化治疗的重要性。
核心结论
- 更清楚地识别肌阵挛-失张力性癫痫的独特特征并结合分子遗传学检测的进步,将为更聚焦的临床研究和药物开发铺路。
- 未来研究应致力于识别遗传病因并定制治疗选择,以期为改善长期结局带来希望。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 肌阵挛-失张力性癫痫为儿童期起病的癫痫综合征,发作类型包括肌阵挛-失张力、失张力、肌阵挛、失神及全面强直-阵挛发作。
- 该综合征的病因和结局高度可变,其分类和预后仍存在许多不确定性。
- 约三分之二患儿可获得无认知或行为后遗症的癫痫缓解。
- 部分患儿持续存在耐药性癫痫、智力障碍和行为问题。
- 在相当一部分患者中可发现单基因病因,凸显基因检测对制定个性化治疗策略的重要性。
临床怎么用
- 传统抗癫痫药物和生酮饮食仍是主要治疗选择。
- 识别单基因病因对制定个性化治疗策略具有重要性。
- 原文未据此给出其他推荐。
局限性
- 该综合征的分类和预后仍存在许多不确定性。
- 诊断复杂性阻碍了新疗法试验的开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epilepsy with myoclonic-atonic seizures is a childhood-onset epilepsy syndrome characterised by a range of seizure types, including myoclonic-atonic, atonic, myoclonic, absence, and generalised tonic-clonic seizures. The causes and outcomes of this syndrome are highly variable, with many uncertainties surrounding its classification and prognosis. Traditional antiseizure medications and the ketogenic diet remain the main treatment options. Although two-thirds of children attain remission from seizures without cognitive or behavioural sequelae, some continue to have drug-resistant seizures, intellectual disability, and behavioural problems. The identification of single-gene causes in a substantial subset of patients highlights the importance of genetic testing for development of personalised treatment strategies. However, diagnostic complexities have hindered the development of trials for new therapies. Better recognition of the distinct features of epilepsy with myoclonic-atonic seizures, combined with advances in molecular genetic testing, will pave the way for more focused clinical research and drug development. Future studies should aim to identify genetic causes and tailor treatment options, offering hope for improved long-term outcomes.
引用
- Guerrini R, Scheffer I, Balestrini S, et al. Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies. Lancet Neurol. 2025. PMID: 40120618. doi:10.1016/S1474-4422(25)00032-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。